Biologics, small molecules, steroids, biosimilars, approvals, and treatment access updates.
Page 16 of 26 · 1224 articles
S1P receptor modulators are an emerging oral class of advanced therapy for moderate-to-severe ulcerative colitis; a systematic review that pools multiple RCTs helps clarify how effective and safe the class appears to be...
Vitamin D may support intestinal barrier integrity and immune regulation—pathways central to mucosal healing and disease control in IBD. Understanding the evidence helps patients and clinicians consider vitamin D as a...
Researchers are developing a novel drug-discovery approach to degrade GATA3, a protein that drives Th2 inflammation in ulcerative colitis. New therapies that more directly target immune drivers could eventually help...
People with IBD and other IMIDs sometimes receive overlapping biologic or targeted therapies during treatment changes or combination regimens.
Injection site pain and local reactions can affect comfort and willingness to continue injectable biologic therapy.
Cure8 found this source from as.com, but the page could not be read reliably yet. It is tagged for Budesonide, Steroids, and Medications. Open the original article for the full details.
Cure8 could only read part of this source from PubMed Central, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Research and clinical...
The study highlights factors linked to needing another operation after ileocecal resection for Crohn’s disease and suggests postoperative biologic therapy may lower long-term reoperation risk. That directly affects...
People with Crohn’s may be interested because the review discusses novel natural compounds that target oxidative stress and inflammation — pathways involved in disease activity — and highlights formulation challenges...
The study provides real-world effectiveness and safety data for risankizumab in a largely difficult-to-treat Crohn's population, showing about half achieved corticosteroid-free clinical remission at 24 weeks —...
Adding partial enteral nutrition to ustekinumab was associated with better clinical, endoscopic, radiologic, and nutritional outcomes at 52 weeks in this multicentre real-world cohort of Crohn’s disease patients. This...
This study suggests that people with PSC-IBD may respond differently to some biologic treatments: infliximab and vedolizumab had similar early effectiveness versus IBD alone, but ustekinumab showed a lower early response...
This large pediatric registry study suggests children starting infliximab biosimilars have similar 12‑month clinical outcomes and treatment durability as those starting the originator drug — reassuring for patients and...
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
Market shifts — including more biosimilars, expanding biologic and small-molecule options, and wider online pharmacy access — can affect how quickly and affordably new Crohn’s treatments reach patients. Patients on...
Patients with IBD who are frail appear to have a substantially higher risk of infections while on biologic therapies compared with fit patients. Recognizing frailty before and during treatment could improve risk...
This trial could provide long-term safety data on guselkumab for children with moderate-to-severe Crohn's disease or ulcerative colitis and offers continued access to the drug for participants from earlier pediatric...
People with IBD sometimes are excluded from or uncertain about immune checkpoint inhibitor cancer trials because of concerns about triggering autoimmune flares. This trial explicitly studies safety and disease impact in...
A Phase 3 trial is testing whether guselkumab can produce MRI-detected transmural healing in Crohn's disease — an outcome that could reflect deeper intestinal healing than symptom improvement alone. If successful, it may...
A large network meta-analysis found adalimumab reduces risk of clinical relapse in Crohn’s disease and upadacitinib reduces loss of clinical response; these findings summarize comparative maintenance therapy evidence...
People with IBD who are breastfeeding and are taking guselkumab may want data on how much of the drug gets into breast milk and the estimated infant exposure. This study aims to provide those measurements for the Q4W and...
This Phase 3 trial directly compares two IL-23–targeting biologic therapies in moderate-to-severe Crohn's disease with a 52-week deep remission endpoint, which could inform future treatment choices if results are...
This registered Phase 2 trial tests guselkumab, golimumab, and a new investigational agent (JNJ-78934804) in adults with moderate–severe ulcerative colitis who previously failed advanced therapies. Results could affect...
Long-term safety data on biologics and thiopurines are important for people with ulcerative colitis because they help patients and clinicians weigh risks (including malignancies and pregnancy-related outcomes) when...
Real-world data may help show how guselkumab performs in routine clinical practice for adults with moderate-to-severe UC who haven’t had prior biologics, information that could be useful to patients and clinicians...
A new IL-23–targeting therapy (JNJ-78934804) is being tested against an approved IL-23 inhibitor (guselkumab) in a large Phase 3 trial for moderate–severe ulcerative colitis, which could affect future treatment options...
A new Phase 3 trial is testing icotrokinra, an oral investigational drug, for induction and maintenance of remission in moderate–severe ulcerative colitis. Trials like this could expand treatment options if the drug...
Accepted applications for a vedolizumab biosimilar could lead to another treatment option for adults with moderate‑to‑severe ulcerative colitis and Crohn’s disease and may improve access or affordability if approved.
The study suggests why a JAK1 inhibitor (filgotinib) may work better in some gut regions than others, offering a possible explanation for mixed clinical trial results in Crohn's disease. This could influence how future...
If approved, a vedolizumab biosimilar could increase access to an established IBD biologic by offering a lower-cost alternative, potentially reducing barriers to starting or continuing treatment for people with...
An updated FDA drug label affects how ustekinumab is prescribed and monitored. It confirms Crohn’s disease and ulcerative colitis as approved uses and highlights safety concerns (infections, TB screening, malignancy)...
People with IBD and those on commonly used biologics may have different early T cell responses and faster waning after SARS-CoV-2 vaccination, which could affect timing or interpretation of immune monitoring and booster...
Disability related to IBD affects daily functioning and quality of life; identifying factors linked with higher or lower disability (vitamin D status, azathioprine use, smoking) can help patients and clinicians consider...
The study tests whether adding MRI-based transmural assessment to a fecal-calprotectin–guided (CALM) strategy improves the ability to keep people with Crohn’s disease in corticosteroid-free clinical remission and may...
The trial tests ustekinumab dosing, safety, and pharmacokinetics specifically in children with moderate–severe Crohn’s — information that can affect pediatric treatment options and dosing guidance once results are...
Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.
Lung involvement is an underrecognized extraintestinal complication in IBD and can reflect disease activity, altered gut–lung immune signaling, or medication toxicity — distinguishing the cause is important for...
Hydrocortisone injection is an FDA‑labelled corticosteroid option for short‑term control of severe flares or life‑threatening situations when oral therapy isn't feasible; the label explicitly names regional enteritis...
The study identifies a compound (DDIE) that reduced cellular senescence and improved colitis in a mouse model by modulating AKT and GSK3B, suggesting a new avenue for drug development in ulcerative colitis focused on...
Personalizing adalimumab dosing could reduce underexposure, treatment failure, and immunogenicity for people with IBD. Validated popPK models are a key step toward reliable model-informed precision dosing in clinical...
The study links symptom trajectories during the first year of biologic treatment to endoscopic remission, suggesting that week 20 symptom assessment may help predict long-term outcomes for people with UC on biologics.
Remote text monitoring is appealing as a low-cost way to support people with IBD on biologics, but this trial suggests it may not boost quality of life or adherence over 4 months when adherence is already high. Patients...
This study suggests a specific gut microbe might reduce gut inflammation in a mouse colitis model and may boost the benefit of infliximab, which could point toward microbiota‑based adjuncts to current IBD therapies.
Vulvar Crohn’s is a rare, often treatment-refractory manifestation. Reports that ustekinumab and risankizumab helped patients may expand options for people with cutaneous Crohn’s disease, especially after anti–TNF...
Based on the title and source metadata, this appears to be a regulatory update related to Medications. The original article is from DailyMed.
Label updates for AVSOLA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and important safety warnings (infection, TB, hepatitis B, and lymphoma risk) that guide...
Patients and clinicians managing ulcerative colitis in India may have greater access to an effective oral treatment (tofacitinib) that can reduce steroid dependence and is available as lower-cost generics. This could...
Patients and clinicians using vedolizumab for ulcerative colitis may expect early improvement, but a lack of remission at week 2 does not reliably predict long-term failure. Clear predictive metrics are needed before...
